drugset / Trial / NCT06044077
A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This study is a randomized, blinded, parallel controlled phase 3 clinical trial to evaluate the immunogenicity and safety of the 23-valent pneumococcal polysaccharide vaccine in healthy people aged 2 years and above.
Timeline
- Start
- 2023-09-08
- Primary completion
- 2024-03-08
- Completion
- 2029-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pneumovax 23 | Vaccine | — | — |
| Subject | control pneumococcal polysaccharide vaccine | Vaccine | — | — |